James Luke Godwin

Merck & Co., Inc., Rahway, NJ, USA (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer”.

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2020)10.1200/jco.19.01213

N/A

4.9DataRank · unranked

294 citations

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt +11 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more